Developing life-changing therapies for complex neurological disorders with axonal dysfunction

Toward a Cure for neuromuscular and neurodegenerative disorders

We’re Augustine Therapeutics, a biotech company driven by a clear purpose: to transform the lives of patients suffering from severe peripheral and central nervous system disorders, in particular the rare hereditary disorder Charcot-Marie-Tooth (CMT), but also other axonal degeneration induced by chemotherapy (CIPN). Our driving force is to advance the knowledge of axonal protection, regeneration, and remyelination and its translation into effective therapies for patients with unmet medical needs.

We are developing  anovel generation of unique samll molecule therapeutics that can achieve reinnervation, aiming to slow down and even reverse the disease and provide significant relief for patients affected by axonopathies. Our assets also have potential therapeutic applications in cardiometabolism, inflammatory and autoimmune diseases.

Learn more about our therapeutic focus

Founded in 2019, Augustine Therapeutics is a biotech company in Leuven, Belgium.

The company is rooted in the groundbreaking research of the laboratory of Professor Ludo Van Den Bosch from the VIB-KU Leuven Center for Brain and Disease Research.

Supported by an advisory board of leading international experts, our experienced team develops innovative, best-in-class therapeutics to address the great unmet need for the treatment of neuromuscular and neurodegenerative disorders.

More about us